Article
A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coli.
BMC biotechnology - 9 Jun 2015
Levin Mattias, Otten Harm, von Wachenfeldt Claes, Ohlin Mats
Abstract excerpt
BACKGROUND: Group 1 grass pollen allergens are a major cause of allergic disease. Specific immunotherapy involving controlled administration of allergens can be used as a disease-modifying treatment for such disease. Recombinant allergen variants with reduced IgE binding capacity may be used as component in such vaccines, as they may induce fewer treatment side effects than materials currently in use. A mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
